Articles tagged with Osteoporosis
A study projects that increasing BMD testing for women with osteoporosis or osteopenia would reduce fractures by 6,683 over three years and result in net Medicare savings of $15.5 million. This could lead to increased patient benefits while reducing costs.
Researchers at the University of Wisconsin-Madison have discovered a potent Vitamin D analog, known as 2MD, which significantly increases bone density in rats with osteoporosis. The compound has shown no apparent toxicity and may become an alternative to hormone replacement therapy.
The US Preventive Services Task Force recommends routine osteoporosis screening to reduce fracture risk in women with low bone density. The optimal frequency of testing is unclear, but intervals of two to five years are most consistent with current understanding.
The USPSTF recommends that physicians routinely screen women over 65 for osteoporosis, a thinning of the bones that can lead to bone fracture. Women at higher than average risk should begin screening at age 60. Early nephrologist care is associated with better outcomes for kidney disease patients, particularly those with African-Americ...
The ACP-ASIM published 'Osteoporosis' guide provides the latest scientific evidence on osteoporosis and essential information on its origins and progress. It addresses every facet of osteoporosis, a common disease that can be identified through non-invasive tests and treated with new effective drugs to reduce fractures.
A new analysis shows that Actonel reduced the risk of nonvertebral osteoporotic fractures by 74 percent within one year in postmenopausal women with osteoporosis. The effect was observed as early as six months, and the study included 1172 patients who received either placebo or Actonel 5 mg daily.
A study found that Actonel significantly slows deterioration in trabecular bone microarchitecture after just one year, while a placebo had no such effect. This suggests that protection of bone microarchitecture may play an important role in bone health.
Researchers analyzed historical placebo control data with Actonel treatment for osteoporosis, revealing a significant reduction in new vertebral fractures. The study found that once-week treatment with Actonel reduced the risk of new vertebral fractures by 77% at one year.
A new analysis reveals that early intervention with Actonel significantly reduces the risk of first vertebral fractures in postmenopausal women. The study found a 75% decrease in fracture risk among women treated with Actonel, compared to those on placebo.
A population-based study found nearly half of women screened for osteoporosis were undiagnosed, while half with the condition didn't receive treatment. Factors influencing therapy included lower bone mineral density and higher education.
A new study by UCSF researchers reveals that osteoporosis has significant economic costs for Californians, with Medicare paying for most hospital care and nursing home care being the largest expense. Early detection and prevention are critical to reducing these costs, which include indirect losses due to premature death.
Women with irregular periods are at increased risk of developing osteoporosis later in life, according to a recent study. The research found that nearly all women with premature ovarian failure reported changes in their menstrual cycle, highlighting the importance of early evaluation and treatment.
A study by UCSF found that consuming excessive salt increases calcium loss, while a potassium supplement helps maintain bone density. Potassium-rich foods like bananas and spinach can be beneficial for preventing osteoporosis in postmenopausal women.
The FDA has approved Actonel 35 mg once-a-week for the treatment and prevention of postmenopausal osteoporosis, showing a significant increase in lumbar spine bone mineral density at 12 months. The study found that once-a-week dosing is therapeutically equivalent to daily dosing.
A Yale research team identified a genetic mutation in the Wnt signaling pathway that leads to high bone density, a trait seen in one in a million people with no symptoms. The findings suggest a new route for developing medications to increase bone density and prevent osteoporosis without clinical side effects.
A study published in the Journal of Clinical Endocrinology and Metabolism has linked six genetic base substitutions to absorptive hypercalciuria, a condition that causes about 45% of all kidney stones. The presence of these base substitutions increases the risk of bone loss and osteoporosis.
Researchers found that raloxifene reduced the risk of cardiovascular events by 40% in postmenopausal women with osteoporosis who were also at high risk for cardiovascular disease. A subset of 1,035 women showed a significant reduction in cardiovascular events compared to placebo.
A new study finds that raloxifene, an osteoporosis medication, reduces breast cancer risk by 76% in postmenopausal women with high estrogen levels. Women with low estrogen levels receive no reduction in risk.
The largest US study on osteoporosis risk factors found that almost half of women over 50 are at risk for the bone disease. The study, led by Dr. Ethel Siris, highlights the need for more women to get tested and treated for osteoporosis, as it can lead to debilitating fractures.
A genetic 'thermostat' called LRP5 regulates bone mass during growth and may contribute to normal variation in bone strength. The discovery could lead to new treatments for rare genetic disorders and potentially increase bone density in the general population.
A new study found that Actonel 35mg taken once a week was equally effective to 5mg daily in improving bone density in postmenopausal women. The treatment also showed a comparable adverse event profile. This alternative dosing regimen may be beneficial for some patients and physicians.
A two-year study of postmenopausal monkeys found tibolone improved bone mineral density while reducing cardiovascular risks compared to estrogen-based treatments. However, it may offer advantages in breast and uterine safety over other options.
A 42-month study published in Archives of Internal Medicine found that sustained-release sodium fluoride safely reduces the risk for vertebral fractures and increases spinal bone mass in older women with osteoporosis. The treatment combination also reduced bone resorption when adequate calcium and vitamin D were provided.
A study presented at the American College of Gastroenterology meeting found that Actonel 5mg daily significantly reduced vertebral fracture risk by 70% in patients on chronic glucocorticoid therapy. Patients who received calcium supplementation and vitamin D also experienced significant reductions in bone loss.
A study of 96 elderly women found that high caffeine intake (over 300mg/day) accelerates bone loss, especially in those with the tt VDR genotype. Moderate caffeine consumption is not linked to increased bone loss, and doctors recommend adequate calcium and moderate caffeine for their patients.
New findings show that Actonel therapy can reduce clinical vertebral fractures in postmenopausal women as early as six months. The data suggests that treatment with Actonel can stop the fracture cascade and improve bone health.
Campers receive controlled dietary intake of calcium, allowing researchers to track bone density changes and determine optimal levels. The goal is to establish guidelines that will help slow bone density decline after middle age.
A strong association has been found between depression and osteoporosis, with depressed individuals experiencing lower bone mineral density. Research suggests that depression may contribute to hormonal abnormalities leading to bone loss and changes in body composition.
A retrospective analysis found that Risedronate reduced nonvertebral fracture risk by 69% at six months, compared to a 54% reduction in risk for patients taking Alendronate. This study suggests that Risedronate is an effective treatment option for osteoporosis prevention and treatment.
A low dose of estrogen was as effective as a higher dose in reducing bone turnover and preventing osteoporosis in older women. The study found that women taking 0.25 mg estradiol had no more side effects than those taking a placebo, improving bone health with fewer risks.
A study found that only 18.5% of patients with fragility fractures received a proper osteoporosis diagnosis, and even fewer were treated accordingly. This gap in care represents a significant lost opportunity to build bone mass and reduce fracture risk among Canada's aging population.
Researchers at the University of Alberta have developed a novel drug delivery system that targets bones directly, potentially treating osteoporosis more effectively. The system uses growth factors to stimulate bone cells and retains the drug in the targeted area, reducing side effects.
A large clinical trial is underway at UCSF to study a combination drug therapy for osteoporosis, using recombinant human parathyroid hormone (1-84) and alendronate. The trial aims to combine agents that speed up bone formation and resorption with those that slow down resorption, resulting in a net gain of bone strength.
The NIH will hold a Consensus Development Conference on Osteoporosis Prevention, Diagnosis, and Therapy, bringing together experts to discuss the latest research findings. The conference aims to clarify factors associated with prevention and better diagnosis and treatment of osteoporosis.
Researchers found a correlation between unexplained foot fractures and low bone density, a primary symptom of osteoporosis. The study suggests that podiatrists should inspect patients with at-risk conditions for early signs of osteoporosis.
A new UCSF study found that bone density loss during osteoporosis treatment is often a sign of regular medication adherence, not a failure of the medication. Women who lost bone density in the first year may actually gain it back with continued treatment.
Researchers discovered statins, commonly used to lower cholesterol, can build new bone and potentially treat osteoporosis. Statin drugs stimulate the production of osteoblasts, specialized cells that create new bone.
Researchers found calcium citrate absorbed 22-27% better than calcium carbonate, effective in preventing bone loss and stabilizing bone density. The studies confirmed the benefits of calcium citrate in maintaining bone health in early menopause.
A new NIAMS-funded study will enroll 5,700 men aged 65+ to investigate the relationship between bone mass, structure, lifestyle, and fractures. The research aims to determine if high bone mass increases the risk of prostate cancer.
Researchers are tracking 5,700 men to determine the relationship between bone mass, structure, and lifestyle with fracture risk in men. The study aims to provide knowledge for designing prevention and treatment approaches for male osteoporosis.
Researchers found that risedronate significantly reduced the incidence of new spinal fractures by 41% and non-vertebral fractures by 39% among postmenopausal women. After one year, risedronate also showed a 65% reduction in new spinal fractures compared to placebo.
A UCSF study found that raloxifene, an osteoporosis prevention drug, significantly reduced the risk of invasive breast cancer in postmenopausal women by 76 percent. The drug also showed promise in preventing both breast and osteoporosis simultaneously.
In a groundbreaking two-year study, nearly two-thirds of postmenopausal women with osteoporosis regained their original bone mass after receiving a new treatment. The synthetic parathyroid hormone treatment was three times more effective than current medications in reversing bone loss.
A study published in the Journal of the American Medical Association found that underlying vitamin D deficiency in post-menopausal women is associated with an increased risk of hip fracture. The researchers discovered that 50% of women with osteoporosis who suffered a hip fracture had previously undetected vitamin D deficiency.
A UCSF study shows that alendronate significantly reduced the risk of spine and hip fractures by almost half among postmenopausal women with osteoporosis. The drug also improved bone density in these women, reducing the risk of fractures by 30 percent compared to placebo.
A new study from Northwestern University found that Evista (raloxifene) significantly reduces the risk of invasive breast cancer in postmenopausal women, with a 63% decrease in newly diagnosed cases. The medication has also been shown to lower cholesterol and protect against bone loss and osteoporosis-related fractures.
A survey of 1,469 women between 40-69 years old found that many are not getting enough counseling about estrogen-replacement therapy. Only 53% felt they made an informed decision about taking hormone replacement, highlighting the need for better education and guidance.
The Women's Health Initiative has reached its recruitment goal for a 15-year study examining the causes of death, disability and frailty in post-menopausal women. The clinical trial involves 68,000 women studying estrogen and progestin effects on heart disease and breast cancer.
A recent study shows that calcitonin-salmon nasal spray significantly reduces the incidence of new spinal fractures in postmenopausal women with existing osteoporosis. The treatment, which is currently indicated for women over 5 years past menopause and without estrogen replacement therapy options.
A two-year study by UCSF researchers found that raloxifene significantly reduced the risk of spinal fractures in osteoporotic postmenopausal women. Women taking raloxifene had a 52% lower risk of first-time spinal fractures, and those with previous spinal fractures had a 38% lower risk compared to placebo
Researchers found that alendronate significantly increased bone mineral density at the spine and hip in men and women taking steroids, reducing fracture risk. The study showed improved outcomes for post-menopausal women receiving 10mg of alendronate.
A new study published in the Annals of Internal Medicine has found that warfarin, a commonly used blood thinner for older women, does not weaken their bones. The study, which tracked over 6,000 post-menopausal women for two years, found no significant difference in bone thinning or fractures between warfarin users and non-users.
A new device approved by the US FDA uses ultrasound technology to estimate bone density of the heel, identifying women at risk of developing osteoporosis. The Sahara Clinical Bone Sonometer can be used in offices and could increase access to testing, especially in rural areas.
Researchers found a strong relationship between bone loss, gum disease, and tooth loss in postmenopausal women. The study suggests that women with osteoporosis may be at higher risk of developing periodontal disease.
A Colorado State University study has found that exposure to high-frequency vibrations can increase bone density in female sheep by up to 3% over a one-year period. This promising treatment may be an ideal alternative for older, less active women with osteoporosis.